| Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) |
Type/Product Area | Terms/Details (Date) |
| MAY 29 31 | |||
| Protea Biosciences Inc.* | Laboratoires Mayloy Spindler | Drug development partnership giving Protea exclusive marketing rights to recombinant lipase for North America | Financial terms were not disclosed (5/29) |
| JUNE 1 25 | |||
| Apthera Inc.* | Kwang Dong Pharmaceutical Co. Ltd. (South Korea) | Licensing agreement for NeuVax in South Korea for breast cancer | Apthera will receive equity investments as well as milestone and royalty payments (6/4) |
| Elusys Therapeutics* | Lonza Sales AG (Switzerland) | Agreement for the production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of anthrax infection | Lonza will provide process development services and manufacturing capacity for that product using Lonza's GS Gene Expression System (6/16) |
|
Notes: # The information in the chart does not cover agricultural agreements or those between biotech companies. * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
To read more on related topics, click on one of the words below.